182 related articles for article (PubMed ID: 36973682)
1. Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report.
Zhang JW; Yang X; Pan B; Xu Y; Lu X; Zhao HT
World J Surg Oncol; 2023 Mar; 21(1):108. PubMed ID: 36973682
[TBL] [Abstract][Full Text] [Related]
2. Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.
Zhang W; Luo C; Zhang ZY; Zhang BX; Chen XP
Front Immunol; 2022; 13():1079342. PubMed ID: 36700218
[TBL] [Abstract][Full Text] [Related]
3. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
Chen WX; Li GX; Hu ZN; Zhu P; Zhang BX; Ding ZY
Medicine (Baltimore); 2019 Nov; 98(45):e17832. PubMed ID: 31702638
[TBL] [Abstract][Full Text] [Related]
4. [A Case of an Advanced Intrahepatic Cholangiocarcinoma Effectively Treated by Conversion Surgery after Neoadjuvant Chemotherapy of Gemcitabine, Cisplatin and S-1].
Ogura N; Hoshino M; Hayashi T; Odaira M; Harada H; Hirose S; Funakoshi S
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1665-1667. PubMed ID: 36733169
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
6. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.
Konstantinidis IT; Do RK; Gultekin DH; Gönen M; Schwartz LH; Fong Y; Allen PJ; D'Angelica MI; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Ann Surg Oncol; 2014 Aug; 21(8):2675-83. PubMed ID: 24664624
[TBL] [Abstract][Full Text] [Related]
7. [A case of unresectable intrahepatic cholangiocarcinoma receiving sustainable pembrolizumab therapy].
Matsushita S; Ueo T; Minami R; Ozawa T; Matsumoto A; Kimura Y; Takeda Y; Okano A; Kusumi F; Ohana M
Nihon Shokakibyo Gakkai Zasshi; 2022; 119(4):360-367. PubMed ID: 35400689
[TBL] [Abstract][Full Text] [Related]
8. Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a
Bian JL; Wang MM; Tong EJ; Sun J; Li M; Miao ZB; Li YL; Zhu BH; Xu JJ
World J Gastroenterol; 2017 Jun; 23(23):4311-4316. PubMed ID: 28694672
[TBL] [Abstract][Full Text] [Related]
9. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Shi GM; Huang XY; Wu D; Sun HC; Liang F; Ji Y; Chen Y; Yang GH; Lu JC; Meng XL; Wang XY; Sun L; Ge NL; Huang XW; Qiu SJ; Yang XR; Gao Q; He YF; Xu Y; Sun J; Ren ZG; Fan J; Zhou J
Signal Transduct Target Ther; 2023 Mar; 8(1):106. PubMed ID: 36928584
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
11. A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy.
Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Arihiro K; Takahashi S
Clin J Gastroenterol; 2022 Dec; 15(6):1164-1168. PubMed ID: 36181621
[TBL] [Abstract][Full Text] [Related]
12. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.
Lunsford KE; Javle M; Heyne K; Shroff RT; Abdel-Wahab R; Gupta N; Mobley CM; Saharia A; Victor DW; Nguyen DT; Graviss EA; Kaseb AO; McFadden RS; Aloia TA; Conrad C; Li XC; Monsour HP; Gaber AO; Vauthey JN; Ghobrial RM;
Lancet Gastroenterol Hepatol; 2018 May; 3(5):337-348. PubMed ID: 29548617
[TBL] [Abstract][Full Text] [Related]
13. Cross-Sectional Imaging of Intrahepatic Cholangiocarcinoma: Development, Growth, Spread, and Prognosis.
Seo N; Kim DY; Choi JY
AJR Am J Roentgenol; 2017 Aug; 209(2):W64-W75. PubMed ID: 28570102
[TBL] [Abstract][Full Text] [Related]
14. Repeated Treatment with
Filippi L; Di Costanzo GG; Tortora R; Pelle G; Cianni R; Schillaci O; Bagni O
Cancer Biother Radiopharm; 2019 May; 34(4):231-237. PubMed ID: 30758985
[No Abstract] [Full Text] [Related]
15. Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.
Kasai K; Kooka Y; Suzuki Y; Suzuki A; Oikawa T; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Takikawa Y
Ann Surg Oncol; 2014 Oct; 21(11):3638-45. PubMed ID: 24817369
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
[TBL] [Abstract][Full Text] [Related]
17. A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy.
Abe K; Wakatsuki T; Katsushima F; Monoe K; Kanno Y; Takahashi A; Yokokawa J; Ohira H
World J Gastroenterol; 2009 Nov; 15(41):5228-31. PubMed ID: 19891026
[TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.
Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R
Front Immunol; 2023; 14():1124482. PubMed ID: 37292215
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.
Ma KW; Cheung TT; She WH; Chok KSH; Chan ACY; Dai WC; Chiu WH; Lo CM
World J Surg; 2018 Mar; 42(3):823-834. PubMed ID: 28905105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
